Trevi Therapeutics

TRVIPhase 3

New Haven, United Statestrevitherapeutics.com

Trevi Therapeutics is dedicated to addressing the debilitating burden of chronic cough through the development of its lead candidate, Haduvio. The company's novel KAMA mechanism targets the cough reflex arc both centrally and peripherally, a differentiated approach in a therapeutic area with high unmet need. With positive Phase 2 data in hand for IPF chronic cough and refractory chronic cough, Trevi is advancing its late-stage clinical programs. The company is a publicly traded entity (NASDAQ: TRVI) headquartered in New Haven, Connecticut.

Market Cap

$1.4B

Focus

Small Molecules

TRVI · Stock Price

USD 10.61+8.51 (+405.24%)

Historical price data

AI Company Overview

Technology Platform

The company's platform is based on the Kappa Agonist/Mu Antagonist (KAMA) pharmacology of nalbuphine, targeting opioid receptors to modulate the cough reflex arc both centrally and peripherally. Its core asset is an extended-release oral formulation of this compound.

Pipeline Snapshot

14 drugs in pipeline, 5 in Phase 3

Drug	Indication	Stage
nalbuphine HCl ER tablets 90 mg BID + nalbuphine HCl ER tablets 180 mg BID + Pla...	Prurigo Nodularis	Phase 2/3
nalbuphine HCl ER tablets 60 mg BID + nalbuphine HCl ER tablets 120mg BID + Plac...	Uremic Pruritus	Phase 2/3
Nalbuphine ER Tablets + Placebo Tablets	Prurigo Nodularis	Phase 2/3
nalbuphine HCl ER	Prurigo Nodularis	Phase 2/3
nalbuphine HCl ER	Uremic Pruritus	Phase 2/3

Funding History

Total raised: $45M

IPOUndisclosedUndisclosedMay 15, 2019

Series B$30MNew Leaf Venture PartnersJun 15, 2015

Series A$15MLilly VenturesJun 15, 2012

Opportunities

Trevi has a major opportunity to be a first-mover in the large, untapped markets of IPF-associated chronic cough and refractory chronic cough (RCC).

Positive Phase 2 data provides a strong foundation for late-stage development and potential partnerships.

The novel KAMA mechanism offers a differentiated profile against emerging P2X3 antagonists.

Risk Factors

Key risks include the inherent uncertainty of Phase 3 clinical trials, the challenge of commercializing against larger competitors like GSK, future capital requirements that may be dilutive, and heightened regulatory scrutiny due to Haduvio's opioid-based mechanism.

Competitive Landscape

Main competitors are GSK (camlipixant, a P2X3 antagonist) and other companies developing P2X3 antagonists for chronic cough. Trevi's Haduvio differentiates itself through its unique Kappa Agonist/Mu Antagonist (KAMA) mechanism, which acts on the opioid receptor pathway rather than the P2X3 pathway targeted by others.

Publications

Patents

Pipeline